uniQure reported full-year 2025 results and a pivotal regulatory update: after a Type A meeting in January, FDA advised that data from AMT-130’s Phase I/II external-control analysis are not sufficient for approval in Huntington’s disease and strongly recommended a prospective, randomized, double-blind, sham surgery–controlled study. The company plans to seek a Type B meeting in the second quarter to align on Phase III design. Alongside this reset, uniQure highlighted pipeline momentum in refractory mesial temporal lobe epilepsy with AMT-260, fresh Phase I/II signals in Fabry disease with AMT-191, and a fortified balance sheet of $622.5 million in cash and investments, guiding runway into the second half of 2029.
The regulatory stance on AMT-130 is a clear marker for CNS gene therapy: robust, randomized evidence is the bar, even when natural history datasets are deep and the disease burden is profound. The company’s 36-month readout in 12 high-dose patients showed a 75% slowing on cUHDRS and a 60% slowing on TFC versus propensity-matched external controls, with reductions in CSF NfL and a tolerable safety profile. Yet FDA’s insistence on sham control underscores a broader post-pandemic recalibration away from external comparators for high-impact, expensive, one-time interventions. The strategic question now is how to operationalize an ethical and feasible neurosurgical sham-controlled design that can recruit, retain, and deliver conclusive outcomes within a realistic budget and timeline.
This matters immediately for patients, payers, and HCPs. For patients and families facing relentless progression, an additional randomized study introduces delay but may ultimately cement confidence in a first disease-modifying option. For payers bracing for multi-hundred-thousand to million-dollar price points, randomized data will be the sine qua non for coverage, outcomes-based contracting, and durability assumptions. For HCPs and centers of excellence, trial participation will hinge on surgical logistics, perioperative risk management, and clarity on endpoints that resonate in real-world care. Competitively, the bar set here weighs on other CNS gene therapy programs pursuing external controls, while potentially advantaging modalities with less invasive delivery or clearer biomarker surrogates.
Across the broader pipeline, uniQure is leaning into indications where concentrated value inflection could reshape the narrative. In refractory MTLE, the company completed enrollment of the first six-patient dose cohort and initiated a second, with updated data expected in the first half of 2026 after an initial 92% seizure reduction in the first treated patient. If replicated, seizure reduction in a high-unmet-need segment could position the program alongside emerging cell therapy entrants and neuromodulation incumbents, with Medical Affairs tasked to define patient selection, monitoring, and center readiness. In Fabry disease, AMT-191 produced striking, durable, dose-dependent α-Gal A elevations and enabled ERT withdrawal in over half of treated patients, but asymptomatic grade 3 liver enzyme elevations triggered a dosing pause in mid and high cohorts. That juxtaposition mirrors an industry-wide pattern in lysosomal storage and systemic AAV programs: promising pharmacodynamics tempered by hepatic safety signals that force dosing and patient-management refinements before commercial viability.
Financially, a net loss of $199 million on $16.1 million in revenues reflects the pivot from contract manufacturing and the investment needed to advance AMT-130 toward Phase III readiness. The extended cash runway and contingent debt capacity tied to regulatory milestones give uniQure time to negotiate study design, execute on epilepsy and Fabry readouts, and calibrate spend to data.
The next move will define the trajectory: can uniQure craft a sham-controlled Phase III that is scientifically rigorous, ethically acceptable, operationally executable, and fast enough to keep patients, investigators, and capital engaged—and will that evidence base be strong enough to satisfy not just FDA, but a payer class demanding hard comparative outcomes for one-and-done CNS therapies?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
